EMBLAVEO 1.5g/0.5g powder for concentrate for solution for infusion PFIZER ORIGINAL MEDICINE
Chemical substance: aztreonam + avibactam
ATC code: J01DF51 • Antiinfectives for systemic use | Other beta-lactam antibacterials | Monobactams
Active substance
Results for the substance aztreonam+avibactam
1 result
About this active substance
Aztreonam+avibactam is a combination of an antibiotic and a beta-lactamase inhibitor used in the treatment of severe bacterial infections caused by resistant gram-negative bacteria. Aztreonam is a monobactam antibiotic that works by inhibiting bacterial cell wall synthesis, while avibactam is a beta-lactamase inhibitor that protects aztreonam from enzymatic degradation.
This combination is indicated for complicated infections such as intra-abdominal infections, urinary tract infections, and severe respiratory infections. It is administered intravenously, with the dose adjusted based on the severity of the infection and the patient's renal function.
Common side effects include nausea, diarrhea, headache, and injection site reactions. In rare cases, severe adverse reactions such as allergic reactions, pseudomembranous colitis, or liver function impairment may occur. Regular monitoring of the patient's condition is essential during treatment.
Aztreonam+avibactam is a valuable therapeutic option for managing resistant bacterial infections, providing an effective solution for patients with limited treatment options.
This combination is indicated for complicated infections such as intra-abdominal infections, urinary tract infections, and severe respiratory infections. It is administered intravenously, with the dose adjusted based on the severity of the infection and the patient's renal function.
Common side effects include nausea, diarrhea, headache, and injection site reactions. In rare cases, severe adverse reactions such as allergic reactions, pseudomembranous colitis, or liver function impairment may occur. Regular monitoring of the patient's condition is essential during treatment.
Aztreonam+avibactam is a valuable therapeutic option for managing resistant bacterial infections, providing an effective solution for patients with limited treatment options.